PMID: 2509521Oct 1, 1989Paper

Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma

Journal of the American Academy of Dermatology
B TankT van Joost

Abstract

In this pilot clinical trail the efficacy of intralesional low-dose human recombinant interferon-gamma was investigated in seven outpatients with nodular basal cell carcinoma. There was no antitumor response in any case. Toxic side effects were minimal. All tumors were excised surgically 8 weeks after completion of therapy.

References

Sep 1, 1986·Journal of the American Academy of Dermatology·H T GreenwayC Nagi

❮ Previous
Next ❯

Citations

Mar 20, 2002·Cancer·Mirjana Urosevic, Reinhard Dummer
Aug 7, 2013·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Katelyn ChitwoodGeorge Cohen
Oct 1, 1991·International Journal of Dermatology·D IkićM Belicza
Mar 1, 1993·The Journal of Clinical Investigation·M YamamuraR L Moy
Jul 8, 2010·Journal of the American Academy of Dermatology·Joslyn S Kirby, Christopher J Miller
Oct 1, 1990·Journal of the American Academy of Dermatology·R C CornellE A Peets
Feb 1, 1991·Journal of the American Academy of Dermatology·S J Miller
Oct 1, 1995·The British Journal of Dermatology·A WollenbergB Przybilla
Jan 1, 1994·The Australasian Journal of Dermatology·A Shiell
Feb 23, 2019·Immunotherapy·Irene RussoMauro Alaibac

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.